afternoon, and good much, very you everyone. thank Glenn,
last this the truly intellectual Chief Oncology unique are potential as to when are recognize of artificial so the currently many that to intelligence accepted companies that of in year, discovery. Executive compelling company's serve applying of because did of drug as assets enormous already I Officer and know, Predictive the among I capital suite I So you November of opportunity
called Carnegie research Mellon for CORE, XXX,XXX only of Biology for way, the Computational drug pathology but C-O-R-E, and computational than called more clinical was our being at XXX,XXX curated our patient-centric [indiscernible] which, developed discovery. and Center engine utility platform and comprehensive proprietary PeDAL These all the our assets discovery by by include not of which computational at also and University, heterogeneous are digitized more both samples tumor currently than slides, biobank biologists
is term. should And heterogeneity many tumor the patients word is particular continuum Each I same say that diagnosed invaluable tumors to differently discovery response therapies. of is Even those with drug are important Understanding heterogeneous drug cancer, each very cancer a unique. that along type of development. the the respond every and though through of
experimentation, assets, than success laboratory being process element Core, and Trilab by our predicting human assets, level own in computer earlier together heterogeneity wet CLIA modeling or certified in in-silico the drug or with and introducing possible. lab of and bench facility PeDAL early failure allowed These capabilities both thought for very those our clinical previously the a by discovery
at the and first, multifaceted risk of critical mitigation a most proposition value offer and drug that biopharmaceutical of includes; companies We stage the discovery. developers, drug clinical persuasive
sooner and development. trials that to validating thereby in targets their likely Second, by identifying are drug avoiding fail unnecessary
the post pipeline drug these cost only patent commercialization exciting not and development discovery, the potentially drugs exists extended potential reduce expand truncating to And is and of clinical replenishing discovery, drug significantly expanded. early-stage of but The to life by the third, pipeline. development,
compound. extremely to of very a to artificial entirely large unsuccessful drug application expensive Prior developers to the drug speculative will to the discovery, clinical of trial type highly and the respond outcome methodology certain tumor determine of relied if intelligence
staggering. across the know, failure As the rate we industry all is
developed. is enter candidates clinical and be will trials that never drug XX% of fail estimated as that It many as
partners ability and confidently essentially a much anticipate our value Our financial to future drug PeDAL and into risk commercial the appear proposition with this. have lower is validation therefore, of to our greater the clinical much platform, By response success. of utilizing likelihood
subsequently that have we been intelligence. with am important And enabled artificial is company in a that is We differentiate I have research developers seems progress commercial and are academic given in my this Predictive science-driven by as and well pleased we the we to able that repositioned do drug ourselves institutions. do market. making, Oncology how distinction, what as to which indicate the view, as we with it resonating
are as we we billion drug down grow visibility is in well earning As is at more market annually and grows, $X discovery positioned a and we compound very to continue path, participate than rate intelligence that which projected momentum And are this the of telling rewarding. XX%. to credibility, both artificial
of the please who a to moment high-level new For benefit overview for me be step those of our may PeDAL to story, and allow a you give platform. back our
unison. in of most XXX,XXX of PeDAL the the experimentation informed at PeDAL our tool is is one tumor application more things by resource PeDAL is not a several These a significant as intelligence a PeDAL interrelated samples. directed rigorous a is scientific disposal, just the artificial by conducted things that which is platform. than functioning laboratory, comprise thing, three biobank
to intelligence, way based the that learning, the or and hence A of artificial human be is thought. key predictions programmed learning, artificial reason differentiator to intelligence intelligence machine data. decisions simple is about human when make capacity to on artificially, of the actually capabilities hand, think upon process AI other intelligence match to learning Machine the is to And thinking, artificial am clear, a mimics It has active which I this. is that referring I or to also a us. for say specifically
system data. very the based is more predictions The supervised, we feed scientists accurate is system, or of statistical upon active, analysis. makes not not information in humans, that is our that able a data predictions form static. that which, sophisticated the programmed have is It information It it more are make to upon provided into case, based the that
by the learning. hence It machine term learns is iteration, that something
platform tumor laboratory a XXX,XXX those samples. essentially in scientific and learning to PeDAL conduct validate machine is Our driven of laboratory informed conducted in biobank We own experimentation supervised by our by experiments viability AI statistically. from silico analysis This just to proposition. is or us apart drug value other This all disprove the discovery companies. is our targets of drug sets scientifically prove what not
retrieved own significance but general capabilities of company analysts, the not not biobank in misunderstood machine The an in we in by and precisely that informed this programming. laboratory. we our testing I tumor artificial a our validated utilize It cannot believe, elsewhere algorithmic by is heterogeneous perhaps way continues human market from because are learning own own it underappreciated methodology, experimentally investors be intelligence and our primarily duplicated or scientific samples driven just by proprietary is that that actual
equally to a XX% important predict drug that or tumor is it tested, respond accuracy PeDAL to compound been PeDAL and has sample technically with scientifically validated and whether Lastly, a understand able to is not. verified. certain
And vitro stage Pat doing and so trials. investing tumor selection decisions testing facilitating is in drug combinations able time before subsequent the inform in of vivo in go/no-go type for later consuming human and to costly
this milestone decision partnered Research questions of tool. Horizon It during decision private funder first have make. we CRH. year Cancer CRH a quarter was occurred very clarify scientific the Cancer and that Research. announcement scientific the world's support with is is A significant the that answers largest PeDAL
the we Why? funder trial. is single this of further utilize I significance Because of CRH single patients, Predictive this of collaboration. private our world. largest can repeat Oncology cancer the platform before preemptively to patient research a point emphasize CRH the heterogeneity clinical has most want partner the to to of chosen with identify PeDAL their to development ever the to compounds. for suitable screen population conducting in
you inhibitors purpose patient certain determining are treatment cancer of even And evaluate horizons specific, globally. depth the types populations be on CRH and more to of breadth likely for partnered and most to with discovery respond these an idea cancer and drug with and the To impact we've compounds. of research to development which to preclinically give drug
Here statistics. are few a
on access an of to cancer than upwards from has more the of of cancer leading generate royalties annually They property research. researchers. network in They excess revenue million intellectual alone. X,XXX a $XXX spent and of $XXX CRH million world's
They currently spinout market. have an critical excess Their of companies of cancer provided compounds. launched have sponsoring portfolio the additional $X.X They in XXX has investments therapies support XX secured that currently are million. on
So value related payments dollar while a we this can were to say not provides able time. over mention to sales-related disclose was when royalty specific the compounds, first that partnership specific milestones for it March, and relationship or we substantial development this in announced
been done potential drug development a strategic one into virtue oncologic the have this have of in itself, collaboration most drug critical community, to and has our stage reach relationship, way that impact never the discovery Through early expanded the exponentially by the of before. we
we precision with develop potential artificial genomic-based empirically, of prescribed the Today, one-size-fits-all treated first tumors to therapy, radiation not radiation to February, radiation the delivered where approach is the field are to ever and has all a RT, announced In which using oncology. partnership intelligence, also utilizing or revolutionize approach therapy we a believe Cvergenx if uniformly.
therapy and next targets and radio significant the for biopharma for paradigm identify shift industry. to the from protectors and prescription and the the radiation of that personalize field of and genomics radiation oncology come most believe We optimize tumor sensitizers drug exploiting radio in will dose development to
is therapy optimizing clinically for Cvergenx provides prescription the Precision individual validated each it the Genomics first personalized medicine. radiation radiation therapy platform to patients, dose approach
If radio the but compounds to the repurposing might this existing prescription entirely of and dose, exists and new apply to one we an discover possibility artificial radiation of sensitizers only class equation, personalization radio take of pursue step and not medicinal we of to protectors, learning intelligence and which further optimization the development for to drugs. lead therapy the potentially machine the
being our is but Center, a hypothetical genomics is Cvergenx trial precision This ever This breast on is first platform clinically spinout the the it clinical a this Cancer the for II where triple is certainly mentioned in it is We call, radiation cancer. not and used approach to market bears currently actionable. prospective negative of therapy. Cvergenx Phase genomics last repeating. precision
we put those more States cancer context, are be just has rate outcomes with clinical than eradicating with X million treated of into that Needless which patients therapy. the treated million very patients To XX,XXX potentially If and role excited to of playing cancer. with the by X%, say, approximately newly in in United translates patients year. equivalent X.X improving is treated this may and almost potentially every about of diagnosed there to cancer are overall lives, those radiation a breast patients improved survival radiotherapy. radiotherapy
drug So entered platform. well discovery, impact The drug collaboration Cvergenx of of into but include our Predictive the radio radio computational the sensitivity extend they diagnostic resistance. and screening PeDAL genomics two the capacity and these platform have scientific radiation or clinical of for repurposing capabilities in and Oncology precision essence, leverage utility Cvergenx beyond to technologies
Based NASA, approach initial upon the significant artificial a to with particular. develop to ever astronaut viewed general is novel conversations the protectors ability identify intelligence the as for and in to radio in aerospace core, benefit genomic-based first example,
of government Department in through provides discovery This drug the energy. that the development. or potentially of along Defense, continuum including extends other and services nuclear drug agencies Oncology to industries, Predictive Keep entire mind
discovery, While drug formulations on the PeDAL drug platform, development. address solubility for and capabilities instance, exclusively focuses our
begin a addition proposals with which the novel announced to biopharma quite Inc. companies, And collaboration diseases. recently on formulation the a likely companies, vaccine Predictive two existing of addition, respiratory related for next-generation quarter. both we finalizing of are third in will pharmaceutical to in end with So Oncology and biotech before contracts Flugen new
and announced a advance drug chromatography, will tools gene the that therapies. our measure and with process throughput which of in to contract interactions Oncology writing and recently, assist self-interaction refer the well-respected pharmaceutical biotech proprietary of HFC Predictive Integra workflow Therapeutics companies Through as utilize high Most biomolecular leader a and rapidly the to this we very accurately gene in next-generation of to extension we development. development collaboration,
collaborations together, that we believe our suite initial Taken technologies. to the of speak these of broad applicability
and in Board as with Board. the like to we call rather research, Board, over experience of Business reviewing innovation. Scientific vast Beginning of I to our well translational Christoph our and would oncology by to Advisory Christoph Reinhardt, PHD pleased development some I our MBA additions a are to Scientific Advisory turn noteworthy Board drug conclude to formation Advisory Directors welcome the team. as Bob, brings Before
research biomarkers. Dr. Reinhardt and and than he oncology Lilly, Eli of responsible was decade, translational for more a portfolio where worked of strategy, For its at implementation for assets
solid beneficial tumors. role drug to Acting Cell cancer with what future of an now be Scientific As Officer Chief patients Phenomics, for he plays novel in instrumental might determining combinations drugs types and
So Predictive Christoph's obviously, is and now of experience, which this the experience, direction Oncology is in critical moving. light strategic timely both in
Marc on respected analytics. pioneer our Science Computational is Robert Scientific Marc Dr. Murphy initiative, and very Vice in Zuckerberg powers and Oncology's in Advisory Dr. Malandro, biological genomics, PeDAL joins expert the Malandro, a the Christoph founding biochemistry University a Carnegie biology, Robert molecular for Board. that is the He Partner Chan President of development and at Operations of Murphy core well and Biology Predictive field platform. machine the at the and was machine Head led technology learning of learning Mellon bioengineering. of
be their leaders Board comprise we contributions. insights and and benefiting a together, thought industry are Advisory to world-class individually These Scientific I from what consider already and
that thought management, names Scientific also We Advisory be advisers a like will Scientific have comprised those announced work of in be board, Board, Directors directly which with senior the leaders also key of will Boards. convened interact and business of business with Advisory coming The but the Board weeks. the relevant and will leaders advisory
And extensive products that experience is has launching the Rao, veteran biotech and digital commercial early a launch building phases. lastly, PHD we pharma and MBA with Dr. health and joined prelaunch Oncology. of recently and of organizations the also Rao Predictive Veena Directors announced Board
Officer Dr. guide company professionals for Board an serve team short-term as down company. and Chief currently long-term science to of but negotiation and Instruments, that the Corporate Rao and business to who strategies. commercial of as is a remain identification, Smith, Director replace will Business and serves evaluation heads she partnership Dr. Counsel of where the and leads adviser opportunities the the as Rao for lead stepping will Portal company's as David
CFO. Myers, will point, our At this I turn call Bob the to over Bob?
